Sorafenib Population Pharmacokinetics and Skin Toxicities in Children and Adolescents with Refractory/Relapsed Leukemia or Solid Tumor Malignancies.
Hiroto InabaJohn C PanettaStanley B PoundsYong-Dong WangLie LiFariba NavidSara M FedericoEric D EisenmannAksana VasilyevaSheila ShurtleffChing-Hon PuiTanja A GruberRaul C RibeiroJeffrey E RubnitzSharyn D BakerPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)
Sorafenib skin toxicities can be affected by concurrent medications and sorafenib steady-state concentrations. The described PPK model can be used to refine exposure-response relations for alternative dosing strategies to minimize skin toxicity.